SAN DIEGO, Oct. 13, 2017 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, announced
today that the Company will host its fiscal fourth quarter and 2017
year-end financial results conference call on Wednesday, October 25th at
1:15 PM PT/4:15 PM ET.
To access the audio broadcast, please dial (877) 731- 1960 and
enter the conference ID number: 86520374. An archived version of
the presentation will be available for 90 days on the "Investors"
section of OncoSec's website:
http://ir.oncosec.com/events-presentations.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based
intratumoral immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse is designed
to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as plasmid encoded IL-12
(tavokinogene telseplasmid or "tavo"). In Phase 1 and 2 clinical
trials, ImmunoPulse® IL-12 has demonstrated a favorable safety
profile, evidence of anti-tumor activity in the treatment of
various solid tumors, and the potential to reach beyond the site of
local treatment to initiate a systemic immune response. OncoSec's
lead program, ImmunoPulse IL-12, is currently in clinical
development for metastatic melanoma and triple-negative breast
cancer. The program's current focus is on the significant unmet
medical need in patients with melanoma who are refractory or have
relapsed on anti-PD-1 therapies. In addition to tavo, the Company
is also identifying and developing new immune-targeting agents for
use with the ImmunoPulse platform. For more information, please
visit www.oncosec.com.
CONTACT:
Investor Relations
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/oncosec-to-host-fourth-quarter-and-year-end-financial-results-conference-call-on-october-25-2017-300536263.html
SOURCE OncoSec Medical Incorporated